Washington, D.C., June 9 (ANI): A biomedical engineer from the University of Houston has shown that renal sympathetic nerve activity (RSNA) and blood pressure are controlled by bioelectronic treatment while treating hypertension with wireless electrodes. RSNA can rise as a result of hypertension and renal illness.
Biomedical engineering professor Mario Romero-Ortega has previously shown how deep peroneal nerve stimulation (DPNS), when utilized with a specifically attached electrode, induces a dramatic reduction in blood pressure. By focusing on the development of a small implanted wireless brain stimulation device and the examination of various stimulation parameters to get the lowest response feasible, the current study builds on earlier research. It appeared in the journal Frontiers in Neuroscience.
To permit implantation into microscopic nerves and to give external power and DPNS modulation control, Romero-Ortega paired a novel nerve attachment microchannel electrode with a sub-millimeter nerve stimulation circuit.
His team demonstrated that after nerve stimulation with this implanted device, systolic blood pressure may drop by 10% in an hour and by 16% in two hours.
Romero studies Ortega’s show that electrical stimulation of the deep peroneal nerve via the DPNS consistently causes an immediate and reproducible arterial depressor effect.
The “silent killer,” as hypertension is sometimes called, is supported by statistics. It is the main reason for death in the nation. It is the largest cause of death in the world, killing more than 1 billion people, and accounts for around half of all heart disease and stroke fatalities. The 2018 American College of Cardiology/American Heart Association guidelines defines hypertension as averaging a systolic blood pressure of more than 130 mmHg and diastolic blood pressure of more than 80 mmHg on at least two separate occasions.
Fifty to sixty percent of resistant hypertension patients still have uncontrolled blood pressure even after effective pharmacological therapy. Unfortunately, despite taking multiple antihypertensive medications in combination, 50–60% of people with high blood pressure have poorly controlled blood pressure, and 12–18% of them develop resistant hypertension, which is defined as blood pressure that is higher than 140/90 mmHg despite taking antihypertensive medications.
Romero-Ortega noted that “in this experiment, DPNS induced an initial spike in RSNA during the first 2-3 seconds, followed by a decline in renal activity and mean arterial pressure” despite an increase in heart rate. It was surprising to see the RSNA appear to be activated during the DPNS given that its activity is connected to hypertension.